These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24655909)

  • 1. [Cardiovascular safety of new type 2 diabetes drugs].
    Hormigo Pozo A; Mancera Romero J
    Semergen; 2014 Mar; 40(2):55-6. PubMed ID: 24655909
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes medications and cardiovascular outcome trials: Lessons learned.
    Patel KV; de Albuquerque Rocha N; McGuire DK
    Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
    Mullard A
    Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular effects of diabetes drugs: emerging from the dark ages.
    Nissen SE
    Ann Intern Med; 2012 Nov; 157(9):671-2. PubMed ID: 23128866
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of cardiovascular events in diabetic patients taking sulphonylureas: need for assessment.
    Rohra DK; Maheshwary AR; Gauba SS
    J Pak Med Assoc; 2007 Mar; 57(3):163. PubMed ID: 17432030
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular trials and diabetes treatments: a regulatory maze.
    Matthews DR
    Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

  • 11. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 12. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

  • 13. [The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk].
    Kern A; Zaleska M; Możeńska O; Bil J
    Wiad Lek; 2017; 70(4):827-833. PubMed ID: 29064812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina.
    Rosenstock J; Marx N; Johansen OE; Wörle HJ;
    Ann Intern Med; 2013 Mar; 158(6):499. PubMed ID: 23553039
    [No Abstract]   [Full Text] [Related]  

  • 16. [DPP4 inhibitors: what is the cardiovascular risk?].
    Langrand C; Moulin P
    Rev Prat; 2015 Oct; 65(8):1039-41. PubMed ID: 26749701
    [No Abstract]   [Full Text] [Related]  

  • 17. Licensing drugs for diabetes.
    Lehman R; Yudkin JS; Krumholz H
    BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral hypoglycemic agents? Negative.
    Chalmers TC
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():32-4; discussion 35-6. PubMed ID: 1347537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?
    Bhardwaj A; Kaur J; Knaus EE
    Future Med Chem; 2013 Mar; 5(4):381-3. PubMed ID: 23495685
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes drugs pass cardiovascular risk check.
    Opar A
    Nat Rev Drug Discov; 2009 May; 8(5):343-4. PubMed ID: 19404302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.